Skip to main content
NVDA+0.90%AAPL-0.99%GOOGL-1.41%MSFT-1.21%AMZN-1.83%TSM-0.65%SPCX-2.09%META-0.04%AVGO-0.68%TSLA-0.29%SKHY+1.19%BRK-B+0.07%LLY+0.76%MU+1.18%JPM-0.83%WMT-0.01%AMD+3.05%V-0.53%XOM+1.32%JNJ-0.92%ASMLa-1.05%0700.HK+1.90%MA-0.93%INTC+1.51%ABBV+0.05%1398.HK-2.09%CSCO+0.70%CVX+1.18%BAC-0.09%ORCL-1.30%COST-1.08%KO-0.60%CAT-0.37%DELL+4.24%HSBA.L-1.09%0005.HK-3.21%UNH-1.36%PG+0.37%LRCX-1.91%AP2d-2.04%AMAT-0.94%NFLX-3.06%GE-2.28%MS-2.21%1816.HK-0.46%3988.HK-2.13%0857.HK+0.60%HD-1.37%PM-0.41%0939.HK-2.83%NZDUSD-0.99%USDJPY+0.94%GBPNZD+0.76%USDTHB+0.72%GBPJPY+0.67%NZDCAD-0.65%CHFJPY+0.62%CADJPY+0.60%NZDCHF-0.60%AUDUSD-0.60%EURNZD+0.52%EURUSD-0.48%EURJPY+0.43%GBPTRY+0.41%AUDNZD+0.40%USDCHF+0.40%AUDJPY+0.36%NZDMXN-0.35%PLNJPY+0.35%USDCAD+0.34%GBPAUD+0.34%NOKJPY+0.33%GBPHKD+0.32%GBPMXN-0.28%SGDJPY+0.25%USDTRY+0.25%AUDCAD-0.24%GBPUSD-0.24%NZDSGD-0.21%EURGBP-0.21%USDSEK+0.20%CHFNOK-0.19%AUDCHF-0.18%USDSGD+0.18%EURCAD-0.17%USDILS+0.16%EURSEK+0.15%GBPCHF+0.14%EURAUD+0.13%EURSGD+0.13%GBPSGD+0.12%CHFSGD-0.11%AUDDKK-0.11%EURCZK+0.11%USDNOK+0.11%GBPCAD+0.10%CHFSEK-0.09%USDPLN+0.08%USDCNH+0.08%EURCHF-0.06%AUDNOK-0.05%EURNOK+0.05%NZDJPY-0.05%GBPZAR-0.05%USDMXN+0.05%CADCHF+0.05%USDDKK+0.04%EURZAR-0.04%EURHKD-0.04%USDCOP-0.04%EURPLN+0.03%USDHKD+0.02%AUDSGD+0.02%EURDKK-0.01%USDZAR+0.01%EURCNH0.00%USOIL+2.22%W1+1.66%UKOIL+1.50%COFFEE-1.07%SUGAR-0.88%C1+0.80%S1+0.73%XNGUSD+0.70%COCOA-0.56%XAUUSD-0.39%GAUUSD-0.39%COTTON-0.38%BTCUSD-3.06%ETHUSD-4.18%USDTUSD-0.04%XRPUSD-2.86%SOLUSD-3.72%TRXUSDT-0.33%ZECUSDT-4.06%DOGEUSD-2.83%XMRUSDT+0.22%LINKUSD-2.88%XLMUSD-0.43%BCHUSDT-1.12%UNIUSD-4.44%LTCUSD-2.35%HBARUSDT-0.86%TONUSD+26.79%SUIUSD-3.04%TAOUSDT-4.20%AAVEUSD-2.59%DOTUSDT-2.51%ICPUSDT-7.90%ONDOUSDT-4.02%WLDUSDT-2.62%ARBUSDT+2.47%ATOMUSDT-2.36%JUPUSDT-5.56%INJUSDT-7.66%STXUSDT-3.49%FETUSDT-4.78%PYTHUSDT-4.98%TIAUSDT-5.86%SEIUSDT-4.71%IMXUSDT-2.62%OPUSDT-3.66%GRTUSDT-4.53%WIFUSDT-5.87%POLUSDT-0.43%IOTAUSDT-6.21%AXSUSDT-3.94%FARTCOINUSDT-2.73%EOSUSDT-4.75%DYDXUSDT-7.13%ORDIUSDT-2.78%GALAUSDT-2.65%NOTUSDT-2.37%RONINUSDT-4.03%NVDA+0.90%AAPL-0.99%GOOGL-1.41%MSFT-1.21%AMZN-1.83%TSM-0.65%SPCX-2.09%META-0.04%AVGO-0.68%TSLA-0.29%SKHY+1.19%BRK-B+0.07%LLY+0.76%MU+1.18%JPM-0.83%WMT-0.01%AMD+3.05%V-0.53%XOM+1.32%JNJ-0.92%ASMLa-1.05%0700.HK+1.90%MA-0.93%INTC+1.51%ABBV+0.05%1398.HK-2.09%CSCO+0.70%CVX+1.18%BAC-0.09%ORCL-1.30%COST-1.08%KO-0.60%CAT-0.37%DELL+4.24%HSBA.L-1.09%0005.HK-3.21%UNH-1.36%PG+0.37%LRCX-1.91%AP2d-2.04%AMAT-0.94%NFLX-3.06%GE-2.28%MS-2.21%1816.HK-0.46%3988.HK-2.13%0857.HK+0.60%HD-1.37%PM-0.41%0939.HK-2.83%NZDUSD-0.99%USDJPY+0.94%GBPNZD+0.76%USDTHB+0.72%GBPJPY+0.67%NZDCAD-0.65%CHFJPY+0.62%CADJPY+0.60%NZDCHF-0.60%AUDUSD-0.60%EURNZD+0.52%EURUSD-0.48%EURJPY+0.43%GBPTRY+0.41%AUDNZD+0.40%USDCHF+0.40%AUDJPY+0.36%NZDMXN-0.35%PLNJPY+0.35%USDCAD+0.34%GBPAUD+0.34%NOKJPY+0.33%GBPHKD+0.32%GBPMXN-0.28%SGDJPY+0.25%USDTRY+0.25%AUDCAD-0.24%GBPUSD-0.24%NZDSGD-0.21%EURGBP-0.21%USDSEK+0.20%CHFNOK-0.19%AUDCHF-0.18%USDSGD+0.18%EURCAD-0.17%USDILS+0.16%EURSEK+0.15%GBPCHF+0.14%EURAUD+0.13%EURSGD+0.13%GBPSGD+0.12%CHFSGD-0.11%AUDDKK-0.11%EURCZK+0.11%USDNOK+0.11%GBPCAD+0.10%CHFSEK-0.09%USDPLN+0.08%USDCNH+0.08%EURCHF-0.06%AUDNOK-0.05%EURNOK+0.05%NZDJPY-0.05%GBPZAR-0.05%USDMXN+0.05%CADCHF+0.05%USDDKK+0.04%EURZAR-0.04%EURHKD-0.04%USDCOP-0.04%EURPLN+0.03%USDHKD+0.02%AUDSGD+0.02%EURDKK-0.01%USDZAR+0.01%EURCNH0.00%USOIL+2.22%W1+1.66%UKOIL+1.50%COFFEE-1.07%SUGAR-0.88%C1+0.80%S1+0.73%XNGUSD+0.70%COCOA-0.56%XAUUSD-0.39%GAUUSD-0.39%COTTON-0.38%BTCUSD-3.06%ETHUSD-4.18%USDTUSD-0.04%XRPUSD-2.86%SOLUSD-3.72%TRXUSDT-0.33%ZECUSDT-4.06%DOGEUSD-2.83%XMRUSDT+0.22%LINKUSD-2.88%XLMUSD-0.43%BCHUSDT-1.12%UNIUSD-4.44%LTCUSD-2.35%HBARUSDT-0.86%TONUSD+26.79%SUIUSD-3.04%TAOUSDT-4.20%AAVEUSD-2.59%DOTUSDT-2.51%ICPUSDT-7.90%ONDOUSDT-4.02%WLDUSDT-2.62%ARBUSDT+2.47%ATOMUSDT-2.36%JUPUSDT-5.56%INJUSDT-7.66%STXUSDT-3.49%FETUSDT-4.78%PYTHUSDT-4.98%TIAUSDT-5.86%SEIUSDT-4.71%IMXUSDT-2.62%OPUSDT-3.66%GRTUSDT-4.53%WIFUSDT-5.87%POLUSDT-0.43%IOTAUSDT-6.21%AXSUSDT-3.94%FARTCOINUSDT-2.73%EOSUSDT-4.75%DYDXUSDT-7.13%ORDIUSDT-2.78%GALAUSDT-2.65%NOTUSDT-2.37%RONINUSDT-4.03%
VT

Viridian Therapeutics, Inc. (VRDN)

NASDAQ • Healthcare

$22.2
+$0.96 (+4.5%)
Market open

Last close at September 14, 2026 at 20:00 UTC

Open$21.47
Previous Close$22.2
Day Range$21.27 - $22.3
Avg. Volume (3M)1.2M
Market Cap$2.5B
52 Week Range
$13.18$34.29
Next EarningsIn 50 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$284K100%
Gross Profitminus cost of goods$284K100%

Fundamentals & Financials

Revenue (TTM)
$71.1M
Net Income (TTM)
-$386.9M
EPS (TTM)
-$3.53
ROA (TTM)
-35.27%
Current Ratio
16.95
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-20.0%Q1 2026-$1.08
+15.1%Q2 2026-$0.9
-1.9%Q3 2026-$1.05
Next

Nov 4

in 50 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -1.9%

Viridian Therapeutics’ earnings trailed consensus as EPS of -$1.05 came in below the -$1.03 estimate (difference -$0.02) for the second fiscal quarter of 2026, reported August 6, 2026. Revenue rose 278.7% to roughly $0.3 million, up from $75,000.00 a year ago, reflecting the company’s clinical-stage profile with work centered on pipeline programs such as VRDN-001, VRDN-002, and VRDN-003. With gross profit matching revenue at roughly $0.3 million, the quarter’s results were dominated by operating expense, as operating income was a loss of about $126.3 million. Net income was a loss of roughly $127.1 million, down 26.2% from a net loss of -$100.7 million a year ago, while EPS of -$1.05 was down 5.0% from -$1.00 in the prior-year period. For the next period, consensus calls for EPS of -$0.99 on revenue of $4.0 million.

View full earnings history

About Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc. is a NASDAQ-listed healthcare company in biotechnology, with $70.8 million in FY2025 revenue. Viridian remains centered on a clinical pipeline rather than a marketed product portfolio, with development work focused on named drug candidates instead of commercial therapies.

Name
Viridian Therapeutics, Inc.
CEO
Stephen F. Mahoney
Website
www.viridiantherapeutics.com
Industry
Healthcare
Year Founded
2006
Employees
252

Today's Snapshot

AI-generated

Yesterday VRDN rose 4.5% to 22.20.

Trading Volume

Above 10d avg 1.2M

1.3M

vs S&P 500 Today

Strong Outperformance

+5.00%

Updated: September 15, 2026 at 12:06 UTC

Technical Indicators

3 Buy2 Neutral3 Sell
VRDN shows a mixed technical picture that supports the neutral overall stance. Trend strength is moderate but not decisive, with ADX around the mid-20s and price caught between short-term averages and the 200-day level, which sits slightly above the market. Momentum measures are tepid to negative while oscillators are near neutral, and on-balance volume is weak, suggesting limited buying conviction. Volatility is modest, with ATR near a dollar, and the classic pivot sits just below current price, offering nearby reference. Technical takeaway: Neutral.
All signals
  • EMA (5 indicators)$21.06 - $23.12
    Sell
  • RSI (14)47.80
    Neutral
  • Stochastic %K (14, 3, 3)13.50
    Buy
  • MACD Level (12, 26)0.14
    Neutral

Peers & Related Assets

IBRXImmunityBio, Inc.
$8.37+5.8%
COGTCogent Biosciences, Inc.
$33.410.0%
EWTXEdgewise Therapeutics, Inc.
$44.62+0.5%
RCUSArcus Biosciences, Inc.
$24.07-2.1%
CLDXCelldex Therapeutics, Inc.
$39.18+6.2%
VERAVera Therapeutics, Inc.
$34.05-2.9%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.